The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial

  1. Billings, L.K.
  2. Agner, B.F.R.
  3. Altuntas, Y.
  4. Grøn, R.
  5. Halladin, N.
  6. Klonoff, D.C.
  7. Tentolouris, N.
  8. Jódar, E.
Aldizkaria:
Journal of Diabetes Science and Technology

ISSN: 1932-2968

Argitalpen urtea: 2020

Alea: 15

Zenbakia: 3

Orrialdeak: 636-645

Mota: Artikulua

DOI: 10.1177/1932296820906888 GOOGLE SCHOLAR
Datuen iturria: Scopus